Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVUMWZ)

Drug Name

PS-1145 Drug Info

Synonyms

PS-1145; 431898-65-6; PS 1145; CHEMBL79004; N-(6-Chloro-9H-beta-carbolin-8-yl)-nicotinamide; MLS006010310; ZINC9090; SCHEMBL1420453; CTK1D2755; KS-00000TTM; CHEBI:94801; DTXSID00433238; EX-A786; MolPort-042-665-715; JZRMBDHPALEPDM-UHFFFAOYSA-N; HMS3229F21; BCP24095; s7691; BDBM50130248; AKOS030526812; CS-5415; ACN-053038; NCGC00165873-02; NCGC00165873-01; SMR004701376; HY-18008; AK547800; FT-0700478; J-690297; BRD-K93023739-001-02-9; N-{6-chloro-9H-pyrido[3,4-b]indol-8-yl}pyridine-3-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Investigative	[1]

Cross-matching ID

PubChem CID: 9949093
ChEBI ID: CHEBI:94801
CAS Number: CAS 431898-65-6
TTD Drug ID: DMVUMWZ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Patented Agent(s)

Investigative Drug(s)

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Inhibitor of nuclear factor kappa-B kinase (IKK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dihydrothieno [2,3-e]indazole derivative 1	DMUJ3XK	N. A.	N. A.	Patented	[2]
Dihydrothieno [2,3-e]indazole derivative 4	DMR4LPO	N. A.	N. A.	Patented	[2]
Dihydrothieno [2,3-e]indazole derivative 3	DM85VQR	N. A.	N. A.	Patented	[2]
Dihydrothieno [2,3-e]indazole derivative 2	DM0D3HU	N. A.	N. A.	Patented	[2]
PMID23099093C17d	DMWS7O9	Discovery agent	N.A.	Investigative	[3]
Arsenite	DMBCO4Q	Discovery agent	N.A.	Investigative	[4]
5-Bromo-6-methoxy-9H-beta-carboline	DM157OQ	Discovery agent	N.A.	Investigative	[5]
MRT67307	DMYRCHG	Discovery agent	N.A.	Investigative	[6]
4-hydroxy-2-nonenal	DM2LJFZ	Discovery agent	N.A.	Investigative	[7]
BMS-345541	DM7D519	Arthritis	FA20	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Nuclear factor NF-kappa-B (NFKB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[9]
Triptolide	DMCMDVR	Autoimmune diabetes	5A10	Phase 3	[10]
Laquinimod	DM3IWS8	Lupus	4A40	Phase 3	[11]
Edasalonexent	DMYVBF6	Duchenne dystrophy	8C70	Phase 3	[12]
MD1003	DMVZ57G	Multiple sclerosis	8A40	Phase 3	[12]
Vadimezan	DMK7CYX	Solid tumour/cancer	2A00-2F9Z	Phase 2	[13]
CAT 1004	DMQBP7R	Duchenne dystrophy	8C70	Phase 2	[14]
Parthenolide	DMCQBFT	N. A.	N. A.	Phase 2	[15]
Recoflavone	DMCSR8I	Inflammatory bowel disease	DD72	Phase 2	[16]
CZEN-002	DMUDMHA	Fungal infection	1F29-1F2F	Phase 2	[17]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Inhibitor of nuclear factor kappa-B kinase (IKK)	TTRPDBG	NOUNIPROTAC	Inhibitor	[1]
Nuclear factor NF-kappa-B (NFKB)	TTSXVID	NFKB1_HUMAN; NFKB2_HUMAN; TF65_HUMAN; RELB_HUMAN; REL_HUMAN	Activator	[1]

------------------------------------------------------------------------------------

References

1	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
2	Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
3	Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKepsilon kinases. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7169-73.
4	Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem. 2000 Nov 17;275(46):36062-6.
5	Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2419-22.
6	Novel cross-talk within the IKK family controls innate immunity. Biochem J. 2011 Feb 15;434(1):93-104.
7	IkappaB kinase, a molecular target for inhibition by 4-hydroxy-2-nonenal. J Biol Chem. 2001 May 25;276(21):18223-8.
8	A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum. 2003 Sep;48(9):2652-9.
9	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
10	Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene. 2001 Nov 29;20(55):8009-18.
11	Reduced astrocytic NF- B activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012 Sep;124(3):411-24.
12	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13	Auckland Cancer Society Research Centre report
14	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15	Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med. 2005 Jan 3;201(1):105-15.
16	DA-6034, a derivative of flavonoid, prevents and ameliorates dextran sulfate sodium-induced colitis and inhibits colon carcinogenesis. Exp Biol Med (Maywood). 2008 Feb;233(2):180-91.
17	US patent application no. US20100278784 A1.